Skip to main content

Active clinical trials

Our ongoing investment in clinical trials supports our commitment to pushing the boundaries of medical innovation, seeking solutions that improve lives and advance healthcare.

Common & plantar warts

  • 6 US sites: Chicago (Dr Bhatia), Nashville (Dr Gold), Miami (Dr Waibel), Tampa (Dr Tharp), Palm Harbor (Dr Tharp), Chicago (Dr Fleischer)

  • Approximately 124 patients, randomised to Microwave TX (5-10W, 2-3sec, 3-5 times) vs. cryotherapy (5-10 seconds liquid nitrogen spray, 2 cycles separated by complete thaw)

Primary

  • Clearance of all treated warts at 3 months past final TX

Secondary

  • Clearance of all treated warts using photographs (3, 6 and 12 months)

  • Clearance by the number of warts treated (3 months)

  • Change from baseline for size of treated warts post final treatment (3, 6 and 12 months)

  • Pain score (3, 6 and 12 months)

  • Clearance of all treated warts (6 and 12 months)

  • Reoccurrence (6 and 12 months)

  • Resolution rate (3 months)

  • Patient satisfaction (6 and 12 months)

  • Adverse events

Actinic keratosis

  • 2 sites (Germany and US): Wuppertal (Dirschka), Miami (Dr Waibel)

  • Approximately 60 patients, randomised to microwave treatment on half of their mapped AK lesions

  • 3-4W, 3 seconds, 3 times with a 20 second gap

Primary

  • Clearance of ≥ 75% treated AK at 2 months after the first TX

Secondary

  • Clearance of ≥ 75% treated AK (4 and 6 months)
  • Proportion of subjects with clearance of all AK study lesions (2, 4 and 6 months)

  • Percentage of AK study lesions cleared (2, 4 and 6 months)
  • Pain score during and after treatment
  • Reoccurance (6 and 12 months)
  • Cosmetic outcomes of treated versus untreated AK lesions (2, 4 and 6 months)
  • Adverse events
  • Patient satisfaction

Fungal nail

  • 1 Canadian site: London, Ontario (Dr Gupta)
  • 45 patients
  • Randomised to microwave therapy at three different time intervals: 7-9W, 1 sec, 5 times

Primary

  • Safety of the three treatment regimens (up to 6 months)
  • 'FDA efficacy' = temporary increase in clear nail at 3 and 6 months

Secondary

  • Safety of the three treatment regimens beyond 6 months
  • Increase in nail clearance (6 months)
  • Mycological cure (6, 9 and 12 months)
  • Effective cure (6, 9 and 12 months)
  • Patient satisfaction

See clinicaltrials.gov for further information:  NCT05674747

https://clinicaltrials.gov/study/NCT05674747?intr=swift%20microwave&rank=3